X-linked hypophosphataemia (XLH) Program in Pharmaceutical Benefits Scheme (PBS) 012-22102650
Expand allThis document outlines details of PBS-subsidised burosumab for patients with X-linked hypophosphataemia (XLH).
XLH and listing dates
XLH is an inherited rare condition that affects bones, muscles, and teeth due to the excessive loss of phosphate.
Listing date: burosumab - 1 November 2022.
See Written Authority Required Drugs, for more details.
Enquiries
Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.
The Resources page contains:
- contact details
- FAQs from Service Officers
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)